Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study (Q33410481)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

0 references

multicenter clinical trial

0 references

multiple myeloma

1 reference

based on heuristic

inferred from title

Athanasios Dimopoulos

object named as

Meletios Dimopoulos

1

0 references

object named as

Roman Hajek

5

0 references

3

object named as

Sagar Lonial

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Kenneth C. Anderson

19

object named as

Kenneth C Anderson

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hartmut Goldschmidt

10

object named as

Hartmut Goldschmidt

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Antonio Palumbo

13

object named as

Antonio Palumbo

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

6

object named as

Thierry Facon

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

11

object named as

Vania Hungria

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

David S Siegel

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Junyuan Qi

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Laura Rosinol

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Catherine Williams

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hilary Blacklock

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Andrew Spencer

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Thorsten Graef

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Joseph E Eid

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jennifer Houp

16

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Linda Sun

17

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Scott Vuocolo

18

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

19 September 2013

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1129-1140

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Management of relapsed and relapsed/refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970398-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970398-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970398-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Pomalidomide: first global approval

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970398-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970398-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970398-X

7 January 2021

based on heuristic

inferred from DOI database lookup

An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970398-X

7 January 2021

based on heuristic

inferred from DOI database lookup

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970398-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970398-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970398-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970398-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970398-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970398-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970398-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970398-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative analysis of two rates

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970398-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(13)70398-X

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33410481&oldid=1743225452"